NCT06053099招募中不适用
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
Intergroupe Francophone de Cancerologie Thoracique37 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2024年1月22日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 300
- 试验地点
- 37
- 主要终点
- Feasibility study
研究概览
简要总结
IFCT-2202 ROSIE study aims to incorporate a broad-panel centralized NGS testing at baseline in all patients with completely resected NSCLC with common EGFR mutation after confirmation of an optimal preoperative extension assessment and with a centralized review of the quality of the surgical excision. Furthermore, the IFCT-2202 ROSIE study also aims to study the molecular events associated with relapse on, or after osimertinib exposure, that should result in the opportunity to accede to optimal treatment in case of metastatic relapse.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed consent.
- •Age ≥ 18 years.
- •Pre-surgical disease evaluation including brain MRI/CT-scan and total body PET-FDG CT-scan prior to surgery.
- •Histologically complete anatomical resection (R0) of stage pIB-IIIA (pTNM 8th edition) NSCLC.
- •Presence of a common EGFR mutation (Del19 or L858R).
- •Archival tumour tissue FFPE blocks from surgery available for centrally molecular analyses.
- •Patient eligible to receive osimertinib adjuvant therapy in a 3-year intent to treat decision; patients could receive if necessary adjuvant chemotherapy before starting osimertinib treatment.
- •Patient who is capable, according to the investigator, of complying with the study's requirements and restrictions.
- •Patient followed in the institution on a regular basis (every 3 to 6 months) according to standard recommendations.
- •Estimated life expectancy > 3 years.
- •Woman patients who are of childbearing potential are eligible:
- •They must have a negative pregnancy test before the first dose of osimertinib.
- •They must agree to use effective methods of contraception throughout the course of treatment and should be maintained for 2 months after the end of treatment.
- •Male subjects who are sexually active with a woman of childbearing potential are eligible if an efficacious contraception method should be used during the treatment and during the 4 months following the last dose.
排除标准
- •History of cancer, except for the following situations:
- •Patients with history of cancer for more than 3 years are eligible if they have been treated and considered cured. Patients with history of in situ carcinoma of the cervix or non-melanoma skin carcinoma are eligible.
- •Neoadjuvant anti-cancer treatment (osimertinib and/or chemotherapy or other anti-cancer treatment).
- •Incompletely resected NSCLC (R1 or R2).
- •Any medical condition that would, according to the investigator's judgment, prevent the patient's participation in the clinical study.
- •Active infection (e.g. patients receiving treatment for infection) including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), or active uncontrolled hepatitis B infection except for the situations described in APPENDIX I. Screening for chronic conditions is not required.
研究组 & 干预措施
Plasma ctDNA and FFPE blocks
Experimental
干预措施: Plasma ctDNA (Other)
Plasma ctDNA and FFPE blocks
Experimental
干预措施: FFPE blocks (Other)
结局指标
主要结局
Feasibility study
时间窗: 18 months
Number of patients included receiving osimertinib after 18 months of enrollment
次要结局
- Incidence, nature, and severity of osimertinib-related adverse events (safety)(About 3 years)
研究者
研究点 (37)
Loading locations...
相似试验
招募中
不适用
Myeloma Registry Platform (MYRIAM)Multiple MyelomaNCT03308474iOMEDICO AG2,200
终止
2 期
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine TumorsNeuroendocrine TumorsPancreatic NeoplasmsAdvanced DiseaseSunitinibNCT01215578Assistance Publique - Hôpitaux de Paris33
尚未招募
不适用
Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Combination of PSA/DRE and Multi Parametric Magnetic Resonance ImagingProstate CancerNCT04993508Heinrich-Heine University, Duesseldorf1,908
已完成
不适用
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerRecurrent Squamous Cell Lung CarcinomaStage IV Squamous Cell Lung Carcinoma AJCC v7NCT02154490SWOG Cancer Research Network1,864
已完成
不适用
A New Biomarker for the Non-invasive Diagnosis of Rejection After Heart TransplantationHeart Transplant RejectionNCT03477383Vastra Gotaland Region134